SCHEMBL25867818

SCHEMBL25867818

C#C[C@@]1(CO)CC[C@H](n2cnc3c(N)nc(C)nc32)O1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PNP P00491 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
HTT P42858 1/20 0.39
PDE4D Q08499 1/20 0.39
PDE3A Q14432 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
DNMT1 P26358 1/20 0.38
DNMT3B Q9UBC3 1/20 0.38
PI4K2A Q9BTU6 1/20 0.37
ADORA3 P0DMS8 4/20 0.36
ADORA2A P29274 3/20 0.36
ADORA1 P30542 1/20 0.36
HSP90AA1 P07900 1/20 0.36
HSP90B1 P14625 1/20 0.36
ADORA2B P29275 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25867310 0.88 NT5E (0.35) PNPLMNATP53HTTPDE4D
SCHEMBL2524440 0.88 PDE4D (0.53) PNPLMNATP53HTTPDE4D
SCHEMBL2520516 0.88 AHCY (0.47) PNPLMNATP53HTTPDE4D
SCHEMBL22855175 0.88 AHCY (0.47) PNPLMNATP53HTTPDE4D
SCHEMBL21709764 0.82 AHCY (0.34) LMNAADORA3ADORA2AADORA1ADORA2B
SCHEMBL25659855 0.80 AHCY (0.45) PNPLMNATP53HTTPDE4D
SCHEMBL9548624 0.79 AHCY (0.45) PNPLMNATP53HTTPDE4D
SCHEMBL19910946 0.79 PNP (0.42) PNPLMNATP53HTTPDE4D
SCHEMBL2520562 0.78 AHCY (0.47) PNPLMNATP53HTTPDE4D
SCHEMBL12214180 0.74 AHCY (0.41) PNPLMNATP53HTTPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230226093-A1 ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME BRII BIOSCIENCES, INC. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226093-A1 ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME ADAR, ADA, ADORA2A PNP 7/4885LMNA 2368/4885TP53 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.